Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's
Posted on January 15, 2013 at 15:48 PM EST
Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult